Medicare Part D spending · FDA facts · help paying
Remicade (infliximab): what Medicare Part D spends and the dated federal facts we hold
CMS's Medicare Part D spending dataset reports gross spending on Remicade of $118.80 million in 2024, across 17,640 claims and 3,243 beneficiaries.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Remicade of $118.80 million in 2024, across 17,640 claims and 3,243 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $118.80 million | 17,640 | 3,243 | $6,735 |
| 2023 | $111.27 million | 15,615 | 2,863 | $7,126 |
| 2022 | $102.56 million | 14,729 | 2,778 | $6,963 |
| 2021 | $102.74 million | 14,890 | 2,767 | $6,900 |
| 2020 | $99.40 million | 14,790 | 2,698 | $6,721 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicare Part B payment limit
CMS publishes a quarterly payment limit for the HCPCS code that its NDC crosswalk links to Remicade. It is a ceiling for providers who bill Medicare Part B, not a price a patient pays, and a code's presence says nothing about whether Medicare covers a product.
| HCPCS code | Quarter | Payment limit | Per dosage descriptor | Effective | Read |
|---|---|---|---|---|---|
| J1745 | 2026 Q4 | $29.86 | 10 MG | October 1, 2026 through December 31, 2026 | November 7, 2026 |
Source: CMS ASP pricing files (october-2026-medicare-part-b-payment-limit-files-final.zip and the matching NDC-HCPCS crosswalk). CMS ASP pricing files page.
Biosimilar status
- Remicade (infliximab) is a reference product in the FDA Purple Book (BLA 103772, approved August 24, 1998). The Purple Book lists 4 biosimilars and 0 interchangeable products that name it as their reference product.
Biosimilars: Inflectra, approved April 5, 2016; Renflexis, approved April 21, 2017; Ixifi, approved December 13, 2017; Avsola, approved December 6, 2019
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
FDA safety program (REMS)
- Remicade (application BLA103772): listed as released, without Elements to Assure Safe Use. Program dated November 18, 2009, last modified August 1, 2011. REMS@FDA program page.
A REMS is a safety program the FDA can require for a drug. Some restrict how it is prescribed or dispensed, for example through certified prescribers or pharmacies. This lists what the FDA's REMS@FDA files tie to the application; it does not say which prescribers or pharmacies take part, or whether a given patient needs the program.
Source: FDA REMS@FDA data files (rems-fda-files-2026-11-07-products-20a9945448dd), read November 7, 2026. REMS@FDA product file.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 10 designations for Infliximab; infliximab, 3 with an approval recorded. The 6 most recent are shown. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| March 5, 2026 | treatment of Behcet disease | Designated | RNR Biomedical inc |
| November 19, 2025 | treatment of Behcet’s disease | Designated | ODDIFACT SAS |
| November 9, 2025 | treatment of pyoderma gangrenosum | Designated | ODDIFACT SAS |
| July 26, 2024 | treatment of Kawasaki disease | Designated | ODDIFACT SAS |
| November 12, 2003 | Treatment of pediatric (0 to 16 years of age) Crohn's Disease | Designated/Approved | Centocor, Inc. |
| November 12, 2003 | Treatment of pediatric (0 to 16 years of age) ulcerative colitis | Designated/Approved | Janssen Biotech, Inc. |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 5 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| MN | 591 | $1,104,438 | All record types |
| KY | 107 | $194,322 | Fee-for-service only |
| WV | 72 | $148,132 | Fee-for-service only |
| AR | 93 | $105,665 | Fee-for-service only |
| DC | 91 | $51,587 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (4 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 76 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Medicaid spending
CMS's Medicaid spending dataset reports $111.53 million for Remicade in 2024. CMS's dataset states spending includes Federal and State reimbursement and dispensing fees and is not reduced by Medicaid rebates paid to the states. Spending is what Medicaid paid, not what a patient pays.
| Year | Spending | Claims |
|---|---|---|
| 2024 | $111.53 million | 46,553 |
| 2023 | $132.74 million | 52,346 |
| 2022 | $159.82 million | 55,853 |
| 2021 | $199.80 million | 60,750 |
| 2020 | $225.39 million | 61,748 |
Source: CMS Medicaid spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. A national drug-level aggregate; it says nothing about any state's coverage rules.
Federal formulary status
VA national formulary
The VA's national formulary files list the ingredient infliximab, which covers every maker's product with that ingredient, not only Remicade. Each row is a VA national drug file entry and its status.
| VA entry | Status | Active NDCs |
|---|---|---|
| INFLIXIMAB INJ,LYPHL | Non-formulary | 2 |
Source: VA Pharmacy Benefits Management national formulary (va-formulary-2026-09), read November 7, 2026. VA formulary page.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated February 28, 2025 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Questions
Does Medicare have a negotiated price for Remicade?
The CMS negotiated-price file we read does not list Remicade, so this page shows no negotiated price. A drug appears in that file only when CMS selects it for negotiation, and not being listed says nothing about what it costs a patient.
Is there help paying for Remicade?
No program in our finder lists this drug yet.
How much does Medicare Part D spend on Remicade?
CMS's Medicare Part D spending dataset reports gross spending on Remicade of $118.80 million in 2024, across 17,640 claims and 3,243 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns the generic-entry upper bound, label history, recalls, trials, assistance and Part D spending, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/remicade.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. This drug is not in the CMS negotiated-price file, so no price source is used. Program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS Medicaid spending by drug; TRICARE and VA formulary files; CMS ASP pricing files; FDA Purple Book; FDA Drugs@FDA and Orange Book data files. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.